Clinical trials: Dementia Disorders
Huntington's Disease
Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease
PRECISION-HD1 is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of WVE-120101 in…
- Trial name
- PRECISION-HD1 (NCT03225833)
- Testing
- WVE-120101
- Where
- 21 sites in Australia, Canada and 5 more
- Volunteers
- 61 people
- Sponsor
- Wave Life Sciences USA, Inc.
Alzheimer Disease
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315
Primary: To assess the safety and tolerability of ascending multiple oral doses of SAM-315, an investigational drug, in healthy young adult and elderly subjects.
- Trial name
- NCT00474552
- Testing
- SAM-315
- Where
- France
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Cognitive Impairment, Alzheimer Disease
Validation of a Smartphone Application for the Assessment of Patients With Mild Cognitive Impairment: MemScreen
The clinical evaluation of a patient with a cognitive complaint requires neuropsychological tests, evaluating the integrity of memory and other cognitive functions.
- Trial name
- MemScreen (NCT03811184)
- Testing
- MemScreen
- Where
- France
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- MemScreen
Dementia, Alzheimer's Disease
Use of Different Treatment Care Methods in Patients With Dementia Associated With Alzheimer's Disease
The purpose of this observational study is to examine patterns of treatment care for patients with Alzheimer's disease (AD) in a real-world arena and to examine the association with different outcomes for patients and informal…
- Trial name
- REMIND (NCT00283725)
- Testing
- No intervention
- Volunteers
- 573 people
- Sponsor
- Ortho-McNeil Neurologics, Inc.
Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease
Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects
The overall objective of this study is to compare the overall pattern of [18F]APN-1607 uptake in subjects with MDAD, subjects with AD dementia, and healthy subjects.
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease, Healthy Volunteers
- Trial name
- NCT04141150
- Testing
- [18F]APN-1607
- Where
- 3 sites in United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- APRINOIA Therapeutics, LLC
Alzheimer Disease
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD).
- Trial name
- NCT06297590
- Testing
- LY3954068, Flortaucipir F18
- Where
- 10 sites in United States, Japan and 1 more
- Volunteers
- 56 people
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment, Dementia
Validation of acceXible's Automated Speech Analysis Method for the Early Detection and Monitoring of Patients With Mild Impairment or Dementia in Primary Care
Dementia, especially dementia caused by Alzheimer's disease, is considered one of the most severe health problems of our time. It is currently known that the disease begins many years before clinical symptoms appear.
- Trial name
- NCT05380297
- Testing
- Speech analysis
- Where
- Spain
- Volunteers
- 273 people, healthy volunteers welcome
- Sponsor
- Accexible
Alzheimer's Disease
Effect of LY450139 on the Long Term Progression of Alzheimer's Disease
Alzheimer's disease (AD) is a fatal degenerative disease of the brain for which there is no cure. AD causes brain cells to die. AD is thought to be caused by an excess of beta-amyloid (β-amyloid), a sticky protein in the brain…
- Trial name
- NCT00594568
- Testing
- LY450139
- Where
- 148 sites in United States, Argentina and 17 more
- Volunteers
- 1,537 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
Safety Study of CTS21166 to Treat Alzheimer Disease
This study is the first human exposure for the drug candidate CTS21166 in healthy male volunteers
- Trial name
- CTS (NCT00621010)
- Testing
- CTS21166 (ZPQ-21166)
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- CoMentis
Alzheimer's Disease
A Study of Gantenerumab in Participants With Mild Alzheimer Disease
Part 1 is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of gantenerumab in participants with mild Alzheimer disease.
- Trial name
- NCT02051608
- Testing
- Gantenerumab
- Where
- 131 sites in United States, Argentina and 20 more
- Volunteers
- 389 people
- Sponsor
- Hoffmann-La Roche
Frontotemporal Dementia
Epidemiological Study in FRONtoTemporal Dementia
An international, multicenter, epidemiological observational study aims to investigate the prevalence of genetic etiologies in patients diagnosed with FTD or clinically suspected for FTD.
- Trial name
- EFRONT (NCT05075187)
- Testing
- Genetic Screening
- Where
- 37 sites in Belgium, Germany and 5 more
- Volunteers
- 2,287 people, healthy volunteers welcome
- Sponsor
- CENTOGENE GmbH Rostock
Alzheimer's Disease, Dementia
Nutritional Programme for Dementia Elderly Patient
The main objective of this study is the improvement of the quality of life and state of health of elderly people with cognitive deterioration and their families through a weight loss prevention programme.
- Trial name
- NCT00479843
- Testing
- Nutritional programme
- Where
- Spain
- Volunteers
- 946 people
- Sponsor
- Société des Produits Nestlé (SPN)
Agitation Associated With Alzheimer's Dementia
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
This is a multicenter, randomized, double-blind, placebo-controlled, flexible-dose study of the efficacy, safety, and tolerability of ITI-1284 in patients with agitation associated with Alzheimer's dementia.
- Trial name
- NCT06651567
- Testing
- ITI-1284
- Where
- 70 sites in United States, Bulgaria and 6 more
- Volunteers
- 320 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Healthy Subjects
Study Evaluating The Coadministration of Begacestat And Donepezil
This study examines the cardiac effects (effects on the heart) of administering donepezil and begacestat together to healthy subjects.
- Trial name
- NCT00959881
- Testing
- Donepezil, Begacestat
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Healthy Volunteers, Moderate to Severe Alzheimer Patients
A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease
This is a dual-centre, Phase I/IIa study, in healthy subjects and subjects with AD to investigate the safety, tolerability, cognitive, and behavioural effects of RPh201.
- Trial name
- NCT01513967
- Testing
- RPh201, botanical drug product
- Where
- 2 sites in Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Regenera Pharma Ltd
Alzheimer Disease
A Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of KHK6640, given as a repeated dose in Japanese patients with Mild to Moderate Alzheimer's Disease.
- Trial name
- NCT03093519
- Testing
- KHK6640
- Where
- Japan
- Volunteers
- 21 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Alzheimer's Disease, Dementia
A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease
The purpose of this study is to demonstrate the safety and efficacy of PF-01913539 in the treatment of patients with mild-to-moderate Alzheimer's Disease.
- Conditions
- Alzheimer's Disease, Dementia, Dimebon, Investigational Drug
- Trial name
- NCT01066481
- Testing
- PF-01913539 5 mg
- Sponsor
- Pfizer
Alzheimer Disease, Dementia
Assistive Technology and Reduced Caregiver Burden
The study investigated a six-week randomized controlled trial study in a small cohort of 16 family caregivers of individuals living with Alzheimer's disease and related dementias.
- Conditions
- Alzheimer Disease, Dementia, Caregiver Burden, Quality of Life
- Trial name
- ck (NCT05352529)
- Testing
- The MapHabit system, Dementia educational videos
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- MapHabit, Inc.
Alzheimer's Disease
Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients
Primary Objective: To assess the safety and tolerability of escalating single and multiple doses of SAR228810 in patients with Alzheimer's disease (AD) Secondary Objective: To evaluate the pharmacokinetic properties of SAR228810…
- Trial name
- NCT01485302
- Testing
- SAR228810
- Where
- 8 sites in Bulgaria, France and 3 more
- Volunteers
- 48 people
- Sponsor
- Sanofi
Alzheimer Disease
A Study of the Efficacy and Safety of Aricept in Patients With Severe Alzheimer's Disease Who Are Living in Skilled Nursing Homes
The purpose of the study is to evaluate the efficacy and safety of Aricept in nursing home patients with severe Alzheimer's disease.
- Trial name
- NCT00630851
- Testing
- Donepezil (Aricept)
- Where
- 53 sites in Sweden
- Volunteers
- 249 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.